Visa's Q3 Beat Lifts Forecasts, But Valuation and Regulatory Risks Keep Enthusiasm in Check

What happened

Visa's fiscal Q3 2026 results beat estimates, prompting Wall Street analysts to raise their 2026-2027 forecasts, but the stock’s premium valuation and persistent regulatory risks keep the outlook balanced. The latest 10-Q showed 14% revenue growth, yet GAAP operating expenses rose 19% due to $563 million in severance costs and a $253 million litigation provision, highlighting that near-term margin improvement remains elusive. Despite the upbeat narrative around stablecoin platforms and AI-agent commerce, filings still lack concrete revenue or volume metrics from these new rails, suggesting the market is pricing in optionality that has yet to materialize. The DeepValue master report echoes this caution, assigning a WAIT rating with conviction 3.5, as the $372.4 price tag already embeds durable core growth plus speculative upside. Without clear evidence that cost actions are yielding operating leverage or that new initiatives are converting to earnings, the risk/reward remains unfavorable for new buyers.

Implication

Visa’s Q3 earnings confirm the resilience of its global payments network, with 10% payments-volume growth and a 33% surge in value-added services revenue, but the stock’s premium valuation leaves no room for error. The July 2026 workforce reduction aims to improve operating leverage, yet the full payoff won't be visible until at least the next quarterly filing, while litigation overhangs—including a $1.1 billion MDL accrual—continue to drain cash. Analysts’ raised forecasts rely on core spending holding up, but cross-border growth faces potential normalization, and new ventures in stablecoins and AI agents remain financially immaterial. Our WAIT rating holds; only if the next report shows personnel expenses growing slower than revenue and provides hard metrics on stablecoin settlement or agentic transaction scale would we consider upgrading. In the meantime, downside risks from multiple compression are real, making a pullback toward the $340 attractive entry a more prudent time to buy.

Thesis delta

The article reinforces our existing thesis: strong earnings and analyst upgrades are not sufficient to justify the current multiple when cost pressures and litigation persist, and new growth drivers lack proven financial impact. We maintain the WAIT rating with conviction 3.5, as the risk/reward remains balanced and no new evidence shifts the call.